GSTC (GlobeStar Therapeutics) Total Liabilities: $1.71 Mil (As of Jun. 2024)


What is GlobeStar Therapeutics Total Liabilities?

GlobeStar Therapeutics GSTC -99.00% Total Liabilities is $1.71 Mil as of Jun. 2024.

GlobeStar Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 was $1.71 Mil.

GlobeStar Therapeutics's quarterly Total Liabilities increased from Dec. 2023 ($1.53 Mil) to Mar. 2024 ($1.62 Mil) and increased from Mar. 2024 ($1.62 Mil) to Jun. 2024 ($1.71 Mil).

GlobeStar Therapeutics's annual Total Liabilities increased from Sep. 2021 ($0.73 Mil) to Sep. 2022 ($1.20 Mil) and increased from Sep. 2022 ($1.20 Mil) to Sep. 2023 ($1.43 Mil).

GlobeStar Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics Total Liabilities Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.75 0.73 1.20 1.43

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.43 1.53 1.62 1.71

GlobeStar Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GlobeStar Therapeutics's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.434+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.43

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=N/A--1.434
=N/A

GlobeStar Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.709+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.71

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=0.084--1.625
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.71 Mil mean?
GlobeStar Therapeutics (GSTC) has a Total Liabilities of $1.71 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlobeStar Therapeutics and its competitors.
Is GlobeStar Therapeutics' Total Liabilities too high?
GlobeStar Therapeutics' current Total Liabilities is $1.71 Mil.
How does GlobeStar Therapeutics' Total Liabilities compare to GBLX and ENDV?
GlobeStar Therapeutics' Total Liabilities of $1.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlobeStar Therapeutics and its competitors. GlobeStar Therapeutics's current Total Liabilities is $1.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlobeStar Therapeutics stock overvalued right now?
GlobeStar Therapeutics (GSTC) has a current Total Liabilities of $1.71 Mil. The current Total Liabilities is $1.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For GlobeStar Therapeutics (GSTC), the current Total Liabilities is $1.71 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.